GLV-1h68在痘苗病毒疗法及监测中的应用。

Use of GLV-1h68 for Vaccinia Virotherapy and Monitoring.

作者信息

Frentzen Alexa, Geissinger Ulrike, Tsoneva Desislava, Stritzker Jochen

机构信息

Genelux Corporation, 3030 Bunker Hill St, San Diego, CA, 92109, USA.

出版信息

Methods Mol Biol. 2015;1317:225-37. doi: 10.1007/978-1-4939-2727-2_13.

DOI:10.1007/978-1-4939-2727-2_13

PMID:26072410

Abstract

Herein we describe the use of the vaccinia virus strain GLV-1h68 as a theragnostic agent in cancer models. To date, GLV-1h68 has been used successfully in more than 50 xenograft tumor models. The recombinant vaccinia virus strain has been equipped with heterologous expression cassettes for a luciferase-fluorescent protein fusion gene, bacterial beta-galactosidase, as well as a bacterial glucuronidase. The methods to investigate and monitor GLV-1h68 mediated virotherapy, including optical imaging and biomarker analysis, will be presented in detail.

摘要

在此，我们描述了痘苗病毒株GLV-1h68在癌症模型中作为一种诊疗试剂的应用。迄今为止，GLV-1h68已成功应用于50多个异种移植肿瘤模型。该重组痘苗病毒株配备了用于荧光素酶-荧光蛋白融合基因、细菌β-半乳糖苷酶以及细菌葡萄糖醛酸酶的异源表达盒。将详细介绍研究和监测GLV-1h68介导的病毒疗法的方法，包括光学成像和生物标志物分析。